Inducible expression of Wnt7b promotes bone formation in aged mice and enhances fracture healing

Abstract

There remain unmet clinical needs for safe and effective bone anabolic therapies to treat aging-related osteoporosis and to improve fracture healing in cases of nonunion or delayed union. Wnt signaling has emerged as a promising target pathway for developing novel bone anabolic drugs. Although neutralizing antibodies against the Wnt antagonist sclerostin have been tested, Wnt ligands themselves have not been fully explored as a potential therapy. Previous work has demonstrated Wnt7b as an endogenous ligand upregulated during osteoblast differentiation, and that Wnt7b overexpression potently stimulates bone accrual in the mouse. The earlier studies however did not address whether Wnt7b could promote bone formation when specifically applied to aged or fractured bones. Here we have developed a doxycycline-inducible strategy where Wnt7b is temporally induced in the bones of aged mice or during fracture healing. We report that forced expression of Wnt7b for 1 month starting at 15 months of age greatly stimulated trabecular and endosteal bone formation, resulting in a marked increase in bone mass. We further tested the effect of Wnt7b on bone healing in a murine closed femur fracture model. Induced expression of Wnt7b at the onset of fracture did not affect the initial cartilage formation but promoted mineralization of the subsequent bone callus. Thus, targeted delivery of Wnt7b to aged bones or fracture sites may be explored as a potential therapy.

References

[1] Lee, W. C., Guntur, A. R., Long, F. & Rosen, C. J. Energy metabolism of the osteoblast: implications for osteoporosis. Endocr. Rev. https://doi.org/10.1210/er.2017-00064 (2017).

[2] Ramchand SK, Seeman E. Advances and unmet needs in the therapeutics of bone fragility. Front. Endocrinol., 2018, 9:505

[3] Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J. Bone Miner. Res., 2012, 27:2419-2428

[4] Jiao H, Xiao E, Graves DT. Diabetes and its effect on bone and fracture healing. Curr. Osteoporos. Rep., 2015, 13:327-335

[5] Clark D, Nakamura M, Miclau T, Marcucio R. Effects of aging on fracture healing. Curr. Osteoporos. Rep., 2017, 15:601-608

[6] Karner CM, Long F. Wnt signaling and cellular metabolism in osteoblasts. Cell. Mol. Life Sci., 2017, 74:1649-1657

[7] Maupin KA, Droscha CJ, Williams BO. A comprehensive overview of skeletal phenotypes associatred with alterations in Wnt/b-catenin signaling in humans and mice. Bone Res., 2013, 1:27-71

[8] MacDonald, B. T. & He, X. Frizzled and LRP5/6 receptors for Wnt/beta-catenin signaling. Cold Spring Harb. Perspect. Biol. 4, https://doi.org/10.1101/cshperspect.a007880 (2012).

[9] Malinauskas T, Jones EY. Extracellular modulators of Wnt signalling. Curr. Opin. Struct. Biol., 2014, 29:77-84

[10] Boyden LM et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med., 2002, 346:1513-1521

[11] Little RD et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet, 2002, 70:11-19

[12] Gong Y et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell, 2001, 107:513-523

[13] Balemans W et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med Genet, 2002, 39:91-97

[14] Brunkow ME et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet., 2001, 68:577-589

[15] Fahiminiya S et al. Mutations in WNT1 are a cause of osteogenesis imperfecta. J. Med. Genet., 2013, 50:345-348

[16] Keupp K et al. Mutations in WNT1 cause different forms of bone fragility. Am. J. Hum. Genet., 2013, 92:565-574

[17] Laine CM et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N. Engl. J. Med., 2013, 368:1809-1816

[18] Pyott SM et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am. J. Hum. Genet., 2013, 92:590-597

[19] Zheng HF et al. WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet, 2012, 8

[20] Medina-Gomez C et al. Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet, 2012, 8

[21] Tu X et al. Noncanonical Wnt Signaling through G Protein-Linked PKCdelta Activation Promotes Bone Formation. Dev. Cell, 2007, 12:113-127

[22] Joeng, K.-S. & Long, F. Wnt7b can replace Ihh to induce hypertrophic cartilage vascularization but not osteoblast differentiation durign endochondral bone development. Bone Res. 2, https://doi.org/10.1038/boneres.2014.1034 (2014).

[23] Zhou H, Mak W, Zheng Y, Dunstan CR, Seibel MJ. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J. Biol. Chem., 2008, 283:1936-1945

[24] Holguin N, Brodt MD, Silva MJ. Activation of Wnt signaling by mechanical loading is impaired in the bone of old mice. J. Bone Miner. Res., 2016, 31:2215-2226

[25] Shen L, Zhou S, Glowacki J. Effects of age and gender on WNT gene expression in human bone marrow stromal cells. J. Cell. Biochem, 2009, 106:337-343

[26] Chen J et al. WNT7B promotes bone formation in part through mTORC1. PLoS Genet., 2014, 10

[27] Nakashima K et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell, 2002, 108:17-29

[28] Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development, 2006, 133:3231-3244

[29] Lim J et al. Dual function of Bmpr1a signaling in restricting preosteoblast proliferation and stimulating osteoblast activity in mouse. Development, 2016, 143:339-347

[30] Payne JB, Golub LM. Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharm. Res., 2011, 63:121-129

[31] Frost H. Tetracycline-based hisotlogical analysis of bone remodeling. Calcif. Tissue Res., 1969, 3:211-237

[32] Alam I et al. Osteoblast-specific overexpression of human WNT16 increases both cortical and trabecular bone mass and structure in mice. Endocrinology, 2016, 157:722-736

[33] Moverare-Skrtic S et al. The bone-sparing effects of estrogen and WNT16 are independent of each other. Proc. Natl Acad. Sci. USA, 2015, 112:14972-14977

[34] Sun W, Shi Y, Lee WC, Lee SY, Long F. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse. Bone, 2016, 85:1-8

[35] Joeng KS et al. Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis. J. Clin. Investig., 2017, 127:2678-2688

[36] Bennett CN et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J. Bone Miner. Res., 2007, 22:1924-1932

[37] Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res., 2011, 26:19-26

[38] Moverare-Skrtic S et al. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat. Med., 2014, 20:1279-1288

[39] Lee HH, Behringer RR. Conditional expression of Wnt4 during chondrogenesis leads to dwarfism in mice. PLoS ONE, 2007, 2

[40] Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell, 2005, 8:727-738

[41] Kakar S et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J. Bone Miner. Res., 2007, 22:1903-1912

[42] Solling ASK, Harslof T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther. Adv. Musculoskelet. Dis., 2018, 10:105-115

[43] Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis, 2007, 45:593-605

[44] Perl AK, Wert SE, Nagy A, Lobe CG, Whitsett JA. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl Acad. Sci. USA, 2002, 99:10482-10487

[45] Urlinger S et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl Acad. Sci. USA, 2000, 97:7963-7968

[46] Lin C et al. Construction and characterization of a doxycycline-inducible transgenic system in Msx2 expressing cells. Genesis, 2009, 47:352-359

[47] Muyrers JP, Zhang Y, Testa G, Stewart AF. Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res., 1999, 27:1555-1557

[48] Narayanan K, Williamson R, Zhang Y, Stewart AF, Ioannou PA. Efficient and precise engineering of a 200 kb beta-globin human/bacterial artificial chromosome in E. coli DH10B using an inducible homologous recombination system. Gene Ther., 1999, 6:442-447

[49] McBride-Gagyi SH, McKenzie JA, Buettmann EG, Gardner MJ, Silva MJ. Bmp2 conditional knockout in osteoblasts and endothelial cells does not impair bone formation after injury or mechanical loading in adult mice. Bone, 2015, 81:533-543

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(AR060456)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)